工程化TACI×CD3双特异性抗体引导T细胞攻击多发性骨髓瘤
靶向BCMA的免疫治疗在多发性骨髓瘤中有效,但BCMA下调或丢失导致耐药。本研究开发了靶向TACI的T细胞重定向双特异性抗体(TACI×CD3 bsAb),可诱导T细胞活化、增殖并对MM细胞产生强细胞毒性,且对BCMA下调、对BCMA×CD3 bsAb无反应的MM细胞也有效,并对患者原代MM细胞有细胞毒性。
要点
- TACI×CD3 bsAb可诱导T细胞活化、增殖并杀伤MM细胞。
- 该抗体对BCMA下调且对BCMA×CD3 bsAb无反应的MM细胞仍有效。
- 对患者原代MM细胞具细胞毒性,有望克服BCMA下调耐药。
核心结论
- 靶向TACI的T细胞重定向双特异性抗体可能成为多发性骨髓瘤的治疗策略,并有望克服BCMA下调相关耐药。
研究设计与样本
- 本研究开发了靶向TACI的T细胞重定向双特异性抗体(TACI×CD3 bsAb),并在MM细胞及患者原代MM细胞中评估其功能。
主要发现
- TACI×CD3 bsAb诱导强烈的T细胞活化、增殖和对MM细胞的强效细胞毒性。
- TACI×CD3 bsAb有效抑制BCMA表达下调且对BCMA×CD3 bsAb无反应的MM细胞生长。
- TACI×CD3 bsAb对患者来源的原代MM细胞介导有效的细胞毒性。
临床怎么用
- 对于BCMA靶向治疗后出现BCMA下调或丢失的多发性骨髓瘤患者,TACI×CD3 bsAb可能提供替代治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapies targeting B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor (TNFR) superfamily, have demonstrated remarkable clinical efficacy in treating relapsed/refractory multiple myeloma (MM). However, a major challenge is the frequent downregulation or loss of BCMA expression in patients receiving BCMA-targeted immunotherapies, which substantially diminishes therapeutic efficacy and contributes to disease progression and treatment resistance after an initial positive response. In this study, we developed a T-cell-redirecting bispecific antibody (bsAb) targeting transmembrane activator and CAML interactor (TACI), another TNFR superfamily member expressed on MM cells. The TACI × CD3 bsAb induced robust T-cell activation, proliferation, and potent cytotoxicity against MM cells. Importantly, it also effectively inhibited the growth of MM cells with downregulated BCMA expression that were unresponsive to BCMA × CD3 bsAb treatment. Moreover, the TACI × CD3 bsAb mediated effective cytotoxicity against primary MM cells derived from patients. Collectively, these findings suggest that TACI-targeted T-cell-redirecting bsAb may represent a promising therapeutic strategy for MM, with the potential of overcoming resistance associated with BCMA downregulation in MM.
引用
- Zhang M, Leong WF, Huo J, et al. Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma. Blood Adv. 2026. PMID: 42234959. doi:10.1182/bloodadvances.2025018210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。